Latest News and Press Releases
Want to stay updated on the latest news?
-
— Lowered price at retail pharmacy to expand access to overweight or obesity treatment to more patients CAMPBELL, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company...
-
— Presentations spotlight VIVUS’s 13-year track record of leadership with QSYMIA® (phentermine andtopiramate extended-release capsules CIV) in the treatment of obesity and overweight CAMPBELL,...
-
— Expanded retail access aims to enhance overweight or obesity treatment accessibility CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the...
-
— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to autologous hematopoietic cell transplantation...
-
— Segment to air on Lifetime on Wednesday, March 19, at 7:30 AM ET/PT CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and...
-
- علاج جديد في مجال التحكم بالوزن أصبح متاحاً الآن- دولة الإمارات العربية المتحدة هي الدولة الأولى التي تطرح دواء QSYMIA في منطقة الشرق الأوسط - ارتفاع معدلات السمنة يكلّف الإمارات العربية المتحدة ما...
-
- A new path in weight management is now available - UAE is the first country in the Middle East to have QSYMIA® available - Rising obesity rates cost UAE nearly $12 billion annually ...
-
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- VIVUS, LLC., a biopharmaceutical...
-
CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
-
Collaborative telehealth platform will provide patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their healthcare journey CAMPBELL, Calif., Oct. 30, 2024 ...